[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1257435A1 - 液態藥物製劑 - Google Patents

液態藥物製劑

Info

Publication number
HK1257435A1
HK1257435A1 HK18116647.3A HK18116647A HK1257435A1 HK 1257435 A1 HK1257435 A1 HK 1257435A1 HK 18116647 A HK18116647 A HK 18116647A HK 1257435 A1 HK1257435 A1 HK 1257435A1
Authority
HK
Hong Kong
Prior art keywords
medicinal preparation
liquid medicinal
liquid
preparation
medicinal
Prior art date
Application number
HK18116647.3A
Other languages
English (en)
Inventor
浩輝 谷坂
村上　達也
Original Assignee
富士膠片株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 富士膠片株式會社 filed Critical 富士膠片株式會社
Publication of HK1257435A1 publication Critical patent/HK1257435A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/09—Pyrimidine radicals with arabinosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK18116647.3A 2016-02-29 2018-12-27 液態藥物製劑 HK1257435A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016037309 2016-02-29
JP2016208563A JP6450356B2 (ja) 2016-02-29 2016-10-25 液状医薬製剤
PCT/JP2017/007720 WO2017150511A1 (ja) 2016-02-29 2017-02-28 液状医薬製剤

Publications (1)

Publication Number Publication Date
HK1257435A1 true HK1257435A1 (zh) 2019-10-18

Family

ID=59808127

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18116647.3A HK1257435A1 (zh) 2016-02-29 2018-12-27 液態藥物製劑

Country Status (12)

Country Link
US (1) US11382927B2 (zh)
EP (1) EP3424509B1 (zh)
JP (1) JP6450356B2 (zh)
KR (1) KR102160866B1 (zh)
CN (1) CN108697726B (zh)
AU (1) AU2017227280B2 (zh)
BR (1) BR112018067808B1 (zh)
CA (1) CA3016020C (zh)
HK (1) HK1257435A1 (zh)
RU (1) RU2715240C1 (zh)
TW (1) TWI752940B (zh)
WO (1) WO2017150511A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI787201B (zh) 2016-08-31 2022-12-21 日商富士軟片股份有限公司 抗腫瘤劑、抗腫瘤效果增強劑及抗腫瘤用套組
MX2018002611A (es) * 2018-01-29 2019-07-30 Fujifilm Corp Agente antitumoral para cancer del tracto biliar y metodo para tratar cancer del tracto biliar.
CA3110224A1 (en) * 2018-09-25 2020-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof
JPWO2023008511A1 (zh) 2021-07-29 2023-02-02

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2182061T3 (es) * 1996-04-09 2003-03-01 Yamasa Corp 1 - (2 - desoxi - 2 - fluor-4- tio-beta-d arabinofuranosil)citosina.
JP2004339172A (ja) 2003-05-19 2004-12-02 Taiyo Yakuhin Kogyo Kk 注射用液状医薬製剤
EP2012799B1 (en) 2006-05-03 2016-08-24 Chimerix, Inc. Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
JP2010519179A (ja) * 2007-01-17 2010-06-03 アンスティトゥ・ドゥ・ルシェルシュ・クリニーク・ドゥ・モントリオール ヌクレオシドおよび四級炭素中心を有するヌクレオチド類似体ならびに使用方法
CN101402662B (zh) * 2008-11-07 2011-06-15 江苏奥赛康药业有限公司 一种奈拉滨的制备方法
US20120149657A1 (en) * 2009-05-12 2012-06-14 Southern Research Institute 2'-fluoro arabino nucleosides and use thereof
CN101642569A (zh) * 2009-08-31 2010-02-10 杭州双马生物工程有限公司 活性天然产物b用于制备抗真菌抗肿瘤产品的用途
RU2559364C2 (ru) 2009-12-18 2015-08-10 Либрамедисина, Инк. СПОСОБ ПОЛУЧЕНИЯ ЗАМЕЩЕННЫХ 1-О-АЦИЛ-2-ДЕЗОКСИ-2-ФТОР-4-ТИО-β-D-АРАБИНОФУРАНОЗ
JP5776564B2 (ja) * 2012-01-20 2015-09-09 日本精工株式会社 ワーク処理装置、及びワーク処理方法
BR112014020416B1 (pt) 2012-03-28 2022-03-29 Fujifilm Corporation Cristal de 1-(2-desoxi-2-flúor-4-tio-ß-darabinofuranosil)citosina e composição farmacêutica contendo o referido cristal
DK2883866T3 (da) 2012-08-13 2019-05-13 Fujifilm Corp MELLEMPRODUKT TIL SYNTESE AF 1-(2-DEOXY-2-FLUOR-4-THIO-beta-D- ARABINOFURANOSYL)CYTOSIN, MELLEMPRODUKT TIL SYNTESE AF THIONUKLEOSID OG FREMGANGSMÅDER TIL FREMSTILLING AF DISSE MELLEMPRODUKTER
JP6245527B2 (ja) * 2014-03-24 2017-12-13 富士フイルム株式会社 チオラン環もしくはチアン環骨格を有する化合物の製造方法

Also Published As

Publication number Publication date
BR112018067808A2 (pt) 2019-01-15
TW201735931A (zh) 2017-10-16
JP2017155031A (ja) 2017-09-07
EP3424509A1 (en) 2019-01-09
KR102160866B1 (ko) 2020-09-28
EP3424509A4 (en) 2019-03-20
TWI752940B (zh) 2022-01-21
WO2017150511A1 (ja) 2017-09-08
US20180360865A1 (en) 2018-12-20
JP6450356B2 (ja) 2019-01-09
BR112018067808B1 (pt) 2024-01-02
AU2017227280B2 (en) 2019-11-21
RU2715240C1 (ru) 2020-02-26
CA3016020A1 (en) 2017-09-08
EP3424509B1 (en) 2020-10-14
US11382927B2 (en) 2022-07-12
KR20180104115A (ko) 2018-09-19
CA3016020C (en) 2020-10-27
AU2017227280A1 (en) 2018-09-13
CN108697726B (zh) 2021-04-16
CN108697726A (zh) 2018-10-23

Similar Documents

Publication Publication Date Title
IL282481A (en) A liquid pharmaceutical preparation
ZA201808476B (en) Stable liquid pharmaceutical preparation
ZA201901590B (en) Liquid pharmaceutical composition
ZA201901736B (en) Liquid pharmaceutical composition
IL277241A (en) A liquid pharmaceutical preparation
HK1257026A1 (zh) 液體藥物組合物
SG11201702298VA (en) Pharmaceutical preparation
HK1257435A1 (zh) 液態藥物製劑
HK1244685A1 (zh) 液體藥物組合物
IL253572A0 (en) A liquid pharmaceutical preparation